Orixha develops proprietary Total Liquid Ventilation (TLV) technology, enabling the extracorporeal circulation of breathable liquid to ventilate the lungs of intubated and comatose patients. Their solution addresses the critical need for rapid cooling and respiratory support in post-cardiac arrest syndrome, aiming to improve clinical outcomes in intensive care settings.
Funding
$11.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Intubated and comatose patients in critical care often require advanced respiratory support due to acute lung injury or failure. Conventional mechanical ventilation can be damaging to the lungs, and rapid cooling is crucial in post-cardiac arrest syndrome to improve neurological outcomes.
Solution
Orixha is developing Total Liquid Ventilation (TLV) technology, branded as LuncoLive, which uses an extracorporeal circulation of breathable liquid to ventilate the lungs. This "lung-protective by design" approach aims to minimize ventilator-induced lung injury while providing respiratory support. Their lead product, Vent2Cool, is designed for ultra-rapid cooling of post-cardiac arrest patients, inducing therapeutic hypothermia within 2 hours to improve survival rates and neurological outcomes. Vent2Breathe is being developed for patients with respiratory distress.
Target Audience
The primary target audience includes intensivists and critical care professionals treating intubated and comatose patients, specifically those with post-cardiac arrest syndrome or respiratory distress.
Features
- LuncoLive platform enables "Lung-protective by design" Total Liquid Ventilation.
- Vent2Cool device facilitates ultra-rapid cooling for post-cardiac arrest patients.
- Extracorporeal circulation of breathable liquid provides respiratory support.
- Aims to reduce ventilator-induced lung injury compared to conventional methods.